Protagonist Therapeutics Inc’s recently made public that its Chief Medical Officer MOLINA ARTURO MD unloaded Company’s shares for reported $0.57 million on Jun 10 ’25. In the deal valued at $57.03 per share,10,000 shares were sold. As a result of this transaction, MOLINA ARTURO MD now holds 83,892 shares worth roughly $4.18 million.
Then, MOLINA ARTURO MD sold 10,000 shares, generating $555,100 in total proceeds. Upon selling the shares at $55.51, the Chief Medical Officer now owns 83,892 shares.
Before that, ARTURO MOLINA bought 10,000 shares. Protagonist Therapeutics Inc shares valued at $570,269 were divested by the Officer at a price of $57.03 per share.
Citigroup initiated its Protagonist Therapeutics Inc [PTGX] rating to a Buy in a research note published on June 17, 2025; the price target was $72. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early December with a ‘”a Neutral”‘ rating. BMO Capital Markets began covering PTGX with “an Outperform” recommendation on December 06, 2024. Wedbush started covering the stock on November 05, 2024. It rated PTGX as “an Outperform”.
Price Performance Review of PTGX
On Monday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock fall -2.31% to $49.87. Over the last five days, the stock has lost -10.45%. Protagonist Therapeutics Inc shares have risen nearly 44.17% since the year began. Nevertheless, the stocks have risen 29.20% over the past one year. While a 52-week high of $60.60 was reached on 03/12/25, a 52-week low of $32.50 was recorded on 02/25/25.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 49.08, which if violated will result in even more drops to 48.30. On the upside, there is a resistance level at 51.08. A further resistance level may holdings at 52.29.
How much short interest is there in Protagonist Therapeutics Inc?
A steep rise in short interest was recorded in Protagonist Therapeutics Inc stocks on 2025-06-13, growing by 0.63 million shares to a total of 5.91 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 5.29 million shares. There was a rise of 10.59%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 24, 2024 when TD Cowen began covering the stock and recommended ‘”a Buy”‘ rating along with a $65 price target.
